Related Experiment Video
Updated: Feb 7, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy
Giuseppe Leone1, Livio Pagano1
1Istituto di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.
Abstract:
Infections remain a significant problem in myelodysplastic syndromes (MDS) in treated as well in non-treated patients and assume a particular complexity. The susceptibility to infections is due, in the absence of intensive chemotherapies, mainly to functional defects in the myeloid lineage with or without neutropenia. Furthermore, MDS includes a heterogeneous group of patients with very different prognosis, therapy and risk factors regarding survival and infections. You should distinguish risk factors related to the disease, like as neutrophils function impairment, neutropenia, unfavorable cytogenetics and bone marrow insufficiency; factors related to the patient, like as age and comorbidities, and factors related to the therapy. When the patients with MDS are submitted to intensive chemotherapy with and without hematopoietic stem cell transplantation (HSCT), they have a risk factor for infection very similar to that of patients with acute myeloid leukemia (AML), and mostly related to neutropenia. Patients with MDS treated with supportive therapy only or with demethylating agent or lenalidomide or immunosuppressive drugs should have a tailored approach. Most of the infections in MDS originate from bacteria, and the main risk factors are represented by neutropenia, thrombocytopenia, and unfavorable cytogenetics. Thus, it is reasonable to give antibacterial prophylaxis to patients who start the therapy with demethylating agents with a number of neutrophils <500 × 109/L, or with thrombocytopenia and unfavorable cytogenetics. The antifungal prophylaxis is not considered cost/benefit adequate and should be taken into consideration only when there is an antecedent fungal infection or presence of filamentous fungi in the surveillance cultures. Subjects submitted to immunosuppression with ATG+CSA have a high rate of infections, and when severely neutropenic should ideally be nursed in isolation, should be given prophylactic antibiotics and antifungals, regular mouth care including an antiseptic mouthwash.
Insights
Infections are complex in myelodysplastic syndromes (MDS) due to myeloid defects and patient factors. Prophylaxis strategies should be tailored based on risk factors like neutropenia and cytogenetics for better outcomes.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Background:
- Infections pose a significant and complex challenge for patients with myelodysplastic syndromes (MDS), impacting both treated and untreated individuals.
- Susceptibility to infections in MDS, even without intensive chemotherapy, stems from functional myeloid lineage defects and potential neutropenia.
- Myelodysplastic syndromes encompass a heterogeneous patient group with diverse prognoses, therapies, and infection risk factors.
Purpose of the Study:
- To analyze the multifaceted nature of infections in myelodysplastic syndromes.
- To differentiate between disease-related, patient-related, and therapy-related risk factors for infections in MDS.
- To guide tailored prophylactic strategies for bacterial and fungal infections in MDS patients based on specific risk profiles.
Main Methods:
- Review and synthesis of existing literature on infection risks in myelodysplastic syndromes.
- Categorization of risk factors including neutrophil function, neutropenia, cytogenetics, bone marrow insufficiency, age, comorbidities, and treatment modalities.
- Evaluation of current prophylactic guidelines for antibacterial and antifungal agents in MDS.
Main Results:
- Bacterial infections are most common in MDS, with neutropenia, thrombocytopenia, and unfavorable cytogenetics as primary risk factors.
- Antibacterial prophylaxis is recommended for patients starting demethylating agents with neutrophil counts <500 × 10^9/L, or with thrombocytopenia and unfavorable cytogenetics.
- Antifungal prophylaxis is generally not cost-effective, reserved for cases with prior fungal infections or positive surveillance cultures.
Conclusions:
- Infections in MDS require a nuanced understanding of various risk factors.
- Tailored prophylactic approaches, particularly antibacterial prophylaxis, are crucial for specific patient subgroups.
- Patients undergoing intensive chemotherapy or immunosuppression (e.g., ATG+CSA) require heightened vigilance and potentially isolation and comprehensive prophylaxis.
Related Concept Videos
Stages of Infection
Relative Risk
Gene Therapy
Relative Velocity in One Dimension
Stages of General Anesthesia
Stages of Sleep
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...

